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Summary: 24 
Atypical genitalia in a boy may have a very wide and diverse aetiology and a definitive 25 
diagnosis is often challenging to reach. Detailed clinical evaluation integrated with extensive 26 
biochemical and genetic studies play an important role in this process.  Such care should be 27 
undertaken in highly specialized centres that can also provide access to a multidisciplinary 28 
team for optimal long-term care. 29 
 30 
Practice points: 31 
1- A boy with suspected DSD should be assessed by an expert clinician who is familiar 32 
with the spectrum of conditions, and should be managed an expert multidisciplinary 33 
team. 34 
2- A thorough clinical examination is necessary as XY DSD is associated with a wide 35 
range of associated conditions 36 
3- Normal biochemical evaluation does not exclude genetic conditions 37 
4- Long term care to people with DSD is an important aspect of management and 38 
should include psychological support 39 
5- To improve the care of people with rare conditions such as DSD, knowledge sharing 40 
across geographical boundaries is of utmost importance 41 
 42 
Research Agenda: 43 
1- Longitudinal studies of physical and psychological outcome in people with XY DSD. 44 
2- Understanding the benefit of reaching a definitive diagnosis in people with XY DSD 45 
 46 
 47 
 48 
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Introduction  49 
Although the birth prevalence of cases where there is true genital ambiguity on expert 50 
examination may be as low as 1 in 4000 births, atypical genitalia may be as common as 1 in 51 
300 births [1]. Thus, infants with atypical genitalia may have a very variable presentation and 52 
rather than treating every affected child in a uniform manner, it is paramount that such a child 53 
is first assessed by clinicians with adequate knowledge about the extent of variation in the 54 
physical appearance of genitalia, the underlying pathophysiology that may give rise to a 55 
disorder of sex development (DSD) and the strengths and weaknesses of the tests that can 56 
be performed in early infancy. Unlike 46, XX DSD where the cause is usually clear, 57 
identification of a cause of XY DSD is often unclear and may be attributed to a disorder of 58 
gonadal development, androgen synthesis or androgen action. Furthermore, many genetic 59 
conditions that give rise to XY DSD are associated with a wide range of manifestations. With 60 
the rapid advances in diagnostic technology including molecular biology our fundamental 61 
understanding of sex and gonadal development has improved. It remains to be seen how 62 
these advances are improving the management of people with DSD. In the field of rare 63 
conditions, it is imperative that the clinician shares experience and knowledge with others 64 
through platforms and forums that facilitate national and international clinical and research 65 
collaboration. 66 
 67 
Conditions Associated With DSD in Boys 68 
Although XY DSD can be broadly categorised into disorders of gonadal development, 69 
androgen synthesis and androgen action (Table 1), around 70% of boys who present to a 70 
specialist clinic with suspected DSD do not fit into any of these categories and are classed as 71 
a non-specific disorder of undermasculinisation [2]. It is possible that environmental factors 72 
may also play a role [3,4] and interfere with the normal development of the penis. Infants with 73 
XY DSD often have associated anomalies and are often small for gestational age [1,5]. 74 
Although several single gene defects and chromosomal rearrangements have been 75 
associated with gonadal dysgenesis [6], optimal gonadal development can also be affected 76 
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by sex chromosome aneuploidies, including mosaicism. Sex chromosome abnormalities are 77 
as common as 1% of pregnancies [7], may affect 1 in 450 newborn infants [8] and may be 78 
present in about 1;1,400 of the population [9]. In infants with suspected DSD, sex chromosome 79 
abnormalities may be as common as 6% [10]. Androgen synthesis disorders include defects 80 
in the testicular steroidogenesis pathway. The defect may interfere only with androgen 81 
production, as in cases with 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) 82 
deficiency, or involve other steroidogenic pathways in the adrenal gland, as in cases of 3β-83 
hydroxysteroid dehydrogenase type 2 (3β-HSD2) deficiency. Androgen synthesis would also 84 
be suboptimal in cases with Leydig cell defects from Leydig cell aplasia or hypoplasia. Leydig 85 
cell defects could also result from hypogonadotropic hypogonadism, leading to micropenis 86 
with or without cryptorchidism [11]. The incidence of androgen synthesis disorders such as 87 
17β-HSD3 deficiency is reported at 1:150,000 births [12]. In persistence of Müllerian ducts 88 
syndrome (PMDS), boys are born with normal male external genitalia with internal female 89 
organs resulting from a defect in anti-Müllerian hormone synthesis or function. Androgen 90 
insensitivity syndrome (AIS) has been reported to be the commonest genetic disorder that is 91 
associated with DSD [13]. The incidence of AIS has been reported to range from 1 in 20,400 92 
to 1 in 100,000 [14,15]. Recent data from the Danish National Patient Registry has reported 93 
that the prevalence of XY women with AIS may be about 4 per 100 000 [16]. Gonadal 94 
dysgenesis is reported to be as common as 1 in 10,000 infants [17] but its prevalence in XY 95 
females is reported to be lower at 1 per 100,000 [16].  96 
 97 
Associated Malformations Including SGA in DSD  98 
Associated anomalies in infants with atypical genitalia have been reported to occur in over 99 
30% of cases [13,18- 20] with several cases having multiple malformations [18]. Although 100 
congenital malformations were reported primarily in cases with a mosaic karyotype or with 101 
syndromic DSD [21,22], they have also been reported with increased frequency in monogenic 102 
cases [18]. In addition to a high rate of associated congenital malformations, XY DSD infants 103 
may also be small for gestational age (SGA) [1,5,13,18,19). Infants with no clear cause of 104 
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undervirilisation are more likely to be SGA rather than those who have a molecular genetically 105 
proven diagnosis of partial androgen insensitivity syndrome [5]. On the other hand, associated 106 
malformations were more prevalent in cases with gonadal developmental disorders and 107 
amongst these, the commonest malformations include those that affect the cardiac, central 108 
nervous system (CNS) and renal system [18]. Many transcription factors are involved in the 109 
development of gonads and other organs and this could explain the high frequency of 110 
associated malformation in gonadal development disorders [6]. A mosaic karyotype may also 111 
influence the type of associated malformation, as boys with 45,X/46,XY DSD tend to have 112 
malformations that resemble Turner Syndrome [21]. Smith-Lemli-Opitz syndrome and P450 113 
oxidoreductase (POR) deficiency are well known to be associated with other anomalies 114 
[22,23]. Other androgen synthetic disorders have been reported to be associated with other 115 
conditions [24]. Associated malformations have also been reported in cases of 17β-HSD3 and 116 
5α-reductase 2 (5ARD2) mutations [18]. Given that renal development may also be androgen-117 
dependent [25] it is notable that renal malformations have also been reported in cases of AIS, 118 
including those with a confirmed AR mutation [18,26]. The high rate of associated anomalies 119 
in XY DSD, especially in cases with no definite diagnosis, should direct the clinician to a 120 
meticulous clinical evaluation, trying to gather all possible information that might facilitate the 121 
genetic diagnosis. 122 
 123 
History & Physical Evaluation 124 
Clinical evaluation should begin with a complete medical history and a thorough general 125 
examination. The medical history should focus on antenatal course and results of the antenatal 126 
tests, specifically any structural abnormalities seen in the prenatal ultrasound, and whether 127 
karyotyping has been determined. Any maternal history of exposure to medication or chemical 128 
disruptors should be reported. Family history should be explored thoroughly, especially 129 
consanguinity, as many conditions that are associated with XY DSD are inherited. It should 130 
also record any neonatal or early infantile fatality and family members with any of the following 131 
conditions: DSD, hypoglycaemia, salt-losing crisis, genital surgery, hormonal replacement and 132 
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infertility or amenorrhea. The physical examination should include a detailed general 133 
evaluation to look for evidence that may suggest associated malformations or a dysmorphic 134 
syndrome. Vital signs, particularly blood pressure, should be determined. The genital exam 135 
should include careful inspection and palpation. The labioscrotal fold should be inspected for 136 
texture, shape, skin pigmentation and the degree of fusion, which could indicate the extent of 137 
the androgen effects. Additionally, the labioscrotal fold and inguinal area should be inspected 138 
and palpated for any evidence of gonads, which may include the need to milk it down for 139 
proper evaluation. The stretched phallus length should be measured and compared to the 140 
normative data. The number and the location of phallus openings should be noted. Lastly, use 141 
of a scoring system such as the external masculinisation score (EMS) will allow an objective 142 
record of the external genitalia [27].  143 
 144 
Biochemical Evaluation  145 
Current consensus guidelines for the evaluation of boys with DSD recommend biochemical 146 
assessment as an essential initial diagnostic step [27]. Basic biochemistry is available in most 147 
paediatric centres and steroid hormone profiling offers the opportunity for fast and 148 
comprehensive analysis for both diagnosis, as well as for monitoring of treatment progress 149 
[28]. Amongst specialist centres there is increasing availability of these investigations [29]. 150 
However, recent European guidelines advise that more complex biochemical endocrine 151 
investigations for DSD should be performed as part of a standardised quality framework in 152 
certified laboratories and clinicians managing boys with DSD should therefore be aware of this 153 
prior to initiating these tests [28]. Table 2 summarises the typical first tier of biochemical 154 
investigations recommended at the likely different ages of presentation with DSD. In the case 155 
of the newborn, biochemistry is often unreliable before the age of 36 hours and should be 156 
deferred until thereafter to ensure accuracy [27]. Future investigations will then be dictated by 157 
the clinical phenotype and the initial results. In terms of diagnostic utility, however it should be 158 
noted that a recent study reviewing the biochemical and genetic investigations performed in 159 
122 boys with 46, XY DSD in a single specialist centre demonstrated that biochemical 160 
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endocrine abnormalities were detected in only around one quarter of affected boys. 161 
Interestingly, a genetic abnormality was detected in 20% of the boys with normal endocrine 162 
biochemistry [2].  Increasingly, it is therefore likely that biochemical investigations will in future 163 
be paired with molecular genetic analysis to provide a more comprehensive opportunity to 164 
offer boys a definitive diagnosis. 165 
 166 
Genetic Evaluation  167 
With improvements in technology, genetic evaluation is more readily accessible for boys with 168 
DSD than ever before. According to a recent international survey of centres caring for people 169 
with DSD, genetic testing may even be considered prior to biochemistry, for example for 170 
establishing a diagnosis in conditions such as 5ARD2 deficiency or 17β-HSD3 deficiency [29]. 171 
The importance of providing affected individuals and families with a definitive genetic 172 
diagnosis lies in the fact that subsequent management may be guided by the possibility of 173 
long term fertility or by future gonadal tumour risk. In addition, genetic counselling can be 174 
offered to families regarding recurrence risk and the possible long-term outcomes of the 175 
condition can be discussed. With advances in next generation sequencing (NGS), it is now 176 
possible to investigate large numbers of genes quickly and more cheaply [30]. The initial step 177 
in genetic evaluation in boys with DSD remains in undertaking karyotype analysis either by 178 
polymerase chain reaction (PCR) or fluorescent in situ hybridization (FISH) to confirm whether 179 
the boy is XX or XY [27]. Thereafter depending on availability, multiplex ligation dependent 180 
probe amplification (MPLA) or comparative genomic hybridisation (CGH) may be appropriate. 181 
Approximately 30% of DSD cases have been reported as having copy number variants (CNVs) 182 
on array-CGH [2,31] and this technology may be particularly useful in cases with additional 183 
malformations [32]. Furthermore, CNVs in the non-coding region of gene associated with DSD 184 
have been reported [33]. Some centres now offer targeted panels for key genes involved in 185 
DSD pathogenesis [2], with the likelihood of detecting an abnormality ranging from 10% [2] to 186 
43% [34] in boys with XY DSD and depending on the number of genes included in the panel. 187 
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Additionally, the targeted panel increases the chance of getting a genetic diagnosis compared 188 
with a single gene test [35]. 189 
 190 
Functional Assessment 191 
Historically, AIS was diagnosed based on the analysis of androgen binding in genital skin 192 
fibroblast [36,37]. This approach has become less popular over time, especially when 193 
investigating PAIS as the yield of molecular genetic diagnosis still remained low despite 194 
abnormal binding studies [36]. The effects of exogenous testosterone or human Chorionic 195 
Gonadotropin (hCG) stimulation on penile growth has been used as an indirect method to 196 
assess androgen sensitivity [38]. A number of regimens have been described in the literature 197 
[39-41]. The largest study to date which employed a randomized controlled design with over 198 
90 cases in each arm showed that the administration of parenteral testosterone enanthate 199 
2mg/kg monthly for 2 months was associated with an increase in penile length of 35% [42]. A 200 
concern with parenteral use of testosterone is the systemic effect of testosterone. Thus, some 201 
clinicians have used topical dihydrotestosterone (DHT) and percutaneous administration of 202 
DHT in a dose of 0.2-0.3 mg/kg once daily for a period of 3-4 months has been reported to 203 
increase phallic length by 0.5 to 2.0 cm in five boys with a penile length less than 2.5cm [43]. 204 
However, topical use may also be associated with raised systemic levels of androgens [44]. 205 
Given the variable response, it is unclear whether the penile response to androgens can be 206 
reliably used as a test of androgen sensitivity. Androgen sensitivity has also been evaluated 207 
biochemically by measuring the sex hormone binding globulin (SHBG) following androgen 208 
exposure as part of hCG stimulation [45] or following stanozolol therapy [46]. Although this 209 
response may sometimes be able to identify cases of androgen insensitivity [47], the variability 210 
of the SHBG response has prevented it from being used regularly. The expression of 211 
apolipoprotein D (APOD), an androgen-responsive protein, in the genital fibroblast following 212 
DHT application has been studied in a relatively small cohort of cases with XY DSD. APOD 213 
expression was strikingly reduced in AIS compared with the normal population and in 214 
comparison with other forms of XY DSD [48]. In a relatively large cohort of cases with 46, XY 215 
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DSD, the expression of APOD in the genital skin fibroblast was reduced in patients with AIS 216 
[49] and its study has also allowed the identification of a group of patients who did not have a 217 
mutation in the AR coding sequence but did have reduced AR expression in genital skin 218 
fibroblast. Recently, gene expression in peripheral blood mononuclear cell following a formal 219 
hCG stimulation test has also been studied as a method of assessing androgen sensitivity 220 
[50]. PIWI-interacting RNAs (piRNAs) were upregulated in the cases that showed a 221 
testosterone response to hCG compared to those in the non-responder group. This finding 222 
provides a helpful insight into the short-term effects of androgens whilst assessing functional 223 
sufficiency or sensitivity of androgens from readily available samples. By combining molecular 224 
genetics with routinely performed endocrine investigations, this approach also allows for a less 225 
invasive procedure than other methods.  226 
 227 
Management 228 
With the exception of disorders that affect glucocorticoid or mineralocorticoid synthesis, no 229 
specific medical therapy is usually required in infancy for most cases of XY DSD. Although the 230 
effect of infantile testosterone therapy on subsequent penile length has been reported [51,52], 231 
sufficient data on the different types of DSD is lacking. There is also some evidence to support 232 
the use of early gonadotrophin therapy in cases of hypogonadotrophic hypogonadism but 233 
long-term studies are lacking [53]. Generally, the most important aspect of XY DSD 234 
management is communication with the parents and resolution of any immediate issues 235 
regarding sex assignment. The management of XY DSD requires a well-trained 236 
multidisciplinary medical team that will provide optimal medical, surgical and psychological 237 
care for the patient and their family [27]. Psychological evaluation is an important aspect of 238 
XY DSD management. The parents of a child with atypical genitalia should be assessed, and 239 
should also be counselled by an experienced psychologist. Parents of new children have a 240 
number of queries and often find it difficult to talk to others [54]. They often find senior clinical 241 
staff a useful source of support but may rely on the premise that the condition can be treated.  242 
 243 
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Sex assignment is influenced by many factors. These factors include etiological causes, 244 
external genital features, internal reproductive anatomy, possibility of spontaneous pubertal 245 
development, the capacity for sexual activity and fertility potential, and the ethnic or cultural 246 
background of the parents [55]. In particular, prenatal androgen exposure is a factor that 247 
should also be considered when making a decision regarding gender assignment, as it has 248 
been theorized that gender identity in patients with 5 α reductase deficiency could be 249 
influenced by the extent of prenatal androgen exposure [56].  250 
 251 
For sex assignment, each patient should be evaluated and managed individually, and the 252 
available outcome studies should be reviewed regularly. It has been generally accepted that 253 
all patients with complete androgen insensitivity syndrome (CAIS) and complete gonadal 254 
dysgenesis are raised as female, as studies have indicated that all identify themselves as 255 
female [57,58]. The decision of the assigning the sex of other XY DSDs is still controversial. 256 
Recently, it has been reported that the trend in sex assignment has changed, and now favours 257 
male sex assignment [59]. This change may have been influenced by the current outcome 258 
studies available. Patients diagnosed with either 17β-HSD3 or 5ARD2 deficiencies during the 259 
neonatal period could virilise during puberty, and 60 % of patients diagnosed with either of 260 
these two disorders have been reassigned from the female to male gender during pubertal 261 
period [60]. Additionally, with advances in vitro fertilization technologies, fertility has been 262 
documented in some cases with 5ARD2 deficiency [61]. This is an important development and 263 
should be considered during the decision of sex assignment. Among patients with partial 264 
androgen insensitivity syndrome (PAIS), androgen biosynthetic defects, and partial gonadal 265 
dysgenesis, gender identity corresponds with the sex of rearing, whether they are raised male 266 
or female [58]. In patients with gonadal dysgenesis, hCG stimulated testosterone secretion 267 
and the clinical response to exogenous testosterone should facilitate the decision of gender 268 
assignment, as these tests may indicate the possibility of spontaneous pubertal development. 269 
 270 
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Long term care, monitoring, education and provision of support to the patient and family are 271 
fundamental aspects of DSD management. During childhood, intermittent visits with the 272 
multidisciplinary medical team allows for the opportunity of the child and parents to express 273 
any concerns they may have, and to provide them the needed medical and psychological 274 
support. Additionally, regular visits reinforce a positive relationship between child and 275 
physician. Given that it is increasingly being realised that some causes of XY DSD such as 276 
NR5A1 gene abnormalities may be associated with a gradual deterioration in testes function 277 
[62], PAIS with a confirmed mutation in AR may be associated with early gynaecomastia [63], 278 
sex chromosome variations may be associated with learning or behaviour concerns, regular 279 
visits provide the forum for monitoring of these concerns. Around the time of puberty, the need 280 
for hormonal therapy should be considered and evaluated. Hormonal therapy should be 281 
initiated with low doses of the appropriate sex steroid hormone, which should be gradually 282 
increased to mimic spontaneous pubertal development [64].  However, unlike the typical case 283 
of constitutional delayed growth and puberty, testosterone therapy can be considered at an 284 
earlier age in boys with confirmed organic hypogonadism. 285 
 286 
Long term studies that look at the outcome of boys with DSD are limited, and most of the 287 
literature is comprised of retrospective studies that are subject to selection bias [65]. The 288 
transition of care from paediatric to adult medicine should be planned early on in the patient’s 289 
life. For optimum care, patients should be seen in a transition clinic where care is joined 290 
between paediatric and adult medicine. There are limited data regarding the transition among 291 
patients with DSD, and a proposed strategy has been published [66]. The concept of transition 292 
in general should be focused on the factors that optimize and ensure the continuity of medical 293 
and psychosocial care, as well as to provide comprehensive care in the adult clinic setting. 294 
Patients with DSD often receive medical and surgical intervention, which could, themselves 295 
lead to complications. In a retrospective study, 24% of patients who have had previous 296 
hypospadias repair experienced complications that required additional corrective surgery and 297 
long-term follow up was recommended [67]. Patients who have retained their testes are at risk 298 
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for developing a gonadal tumour. The risk rate of developing a gonadal tumour depends on 299 
different factors, and is determined by the type of disorders the patient is diagnosed with [68]. 300 
There are several other long-term outcomes such as cardiovascular health, metabolic health 301 
and bone health where there is little information available. Linkage studies have revealed that 302 
some of these outcomes may be affected in people with DSD [69] and it is believed that this 303 
may be related to suboptimal hormone replacement in adulthood. Quality of life (QoL), and in 304 
particular sexual QoL, in DSD should be assessed regularly and managed accordingly 305 
throughout their life. A comprehensive assessment of the patient’s QoL should include an 306 
examination of their friendships, education, work life relations and their sexual life and 307 
activities. While some available studies show an impairment of the sexual QoL among patients 308 
with XY DSDs, the data remains inconclusive [70].  Incorporation of standardized clinician 309 
reported and patient reported outcome measurement as part of routine clinical assessment is 310 
becoming increasingly routine in clinical practice [71]. It is anticipated that collection of such 311 
measures will become an essential component of the delivery of care for boys and men with 312 
DSD.    313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
 322 
Table 1 Classification of 46, XY DSD 
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Disorders of gonadal development 
• Complete gonadal dysgenesis (CGD) 
• Partial gonadal dysgenesis(PGD) 
Disorder of androgen synthesis 
• Smith-Lemli- Opitz syndrome  
• Steroidogenic acute regulatory (StAR) protein deficiency 
• P450 side chain cleavage (scc) deficiency  
• 17-α-hydroxylase/17,20-lyase deficiency 
• 3-β- hydroxysteroid dehydrogenase type 2 (3β-HSD2) deficiency 
• P450 oxidoreductase (POR) deficiency  
• 17-β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) deficiency 
• 5α- reductase 2 (5ARD2) deficiency  
Disorder of androgen action 
• Complete androgen insensitivity syndrome (CAIS) 
• Partial androgen insensitivity syndrome (PAIS) 
Leydig cell defect 
• Leydig cell hypoplasia  
• LH deficiency  
Persistence of Müllerian ducts syndrome (PMDS) 
• Defect in AMH synthesis 
• Defect in AMH receptor 
Other  
 
  323 
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 324 
Age at first presentation Biochemical evaluation Genetic evaluation 
Newborn 17 OH-progesterone 
Electrolytes 
Glucose 
Testosterone  
Androstenedione 
Renin 
AMH 
Urine steroid profile 
Urgent:  
PCR or FISH analysis using Y 
and X-specific markers 
Non-urgent:  
CGH array 
Targeted NGS. 
 
 
Adolescent LH 
FSH 
testosterone  
Prolactin 
 
 325 
Table 2. Investigations for initial presentation of a boy with DSD. Abbreviations: 17OHP: 17 326 
OH-progesterone; AMH: anti-Müllerian hormone; LH: luteinising hormone; FSH: follicle 327 
stimulating hormone; PCR: polymerase chain reaction; FISH: fluorescence in situ 328 
hybridisation; CGH: comparative genomic hybridisation; NGS: next generation sequencing.  329 
 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
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